|
1
|
Schumacher TN and Thommen DS: Tertiary
lymphoid structures in cancer. Science.
375(eabf9419)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Zhao L, Jin S, Wang S, Zhang Z, Wang X,
Chen Z, Wang X, Huang S, Zhang D and Wu H: Tertiary lymphoid
structures in diseases: Immune mechanisms and therapeutic advances.
Signal Transduct Tar. 9(225)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Gao J, Navai N, Alhalabi O, Siefker-Radtke
A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC,
et al: Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with
cisplatin-ineligible operable high-risk urothelial carcinoma. Nat
Med. 26:1845–1851. 2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Liu Y, Ye SY, He S, Chi DM, Wang XZ, Wen
YF, Ma D, Nie RC, Xiang P, Zhou Y, et al: Single-cell and spatial
transcriptome analyses reveal tertiary lymphoid structures linked
to tumour progression and immunotherapy response in nasopharyngeal
carcinoma. Nat Commun. 15(7713)2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Xie M, Lin X, Bao X, Liang Y, Deng H, Song
J, Ma X, Zhang X, Yao J, Pan L and Xue X: Tertiary lymphoid
structure in tumor microenvironment and immunotherapy of lung
cancer. Arch Bronconeumo. 60 (Suppl 2):S77–S85. 2024.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
6
|
Zhao R, Zhang J, Ma J, Qu Y, Yang Z, Yin
Z, Li F, Dong Z, Sun Q, Zhu S, et al: cGAS-activated endothelial
cell-T cell cross-talk initiates tertiary lymphoid structure
formation. Sci Immunol. 9(eadk2612)2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Meylan M, Petitprez F, Becht E, Bougoüin
A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau
J, et al: Tertiary lymphoid structures generate and propagate
antitumor antibody-producing plasma cells in renal cell cancer.
Immunity. 55:527–541.e5. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Fridman WH, Meylan M, Petitprez F, Sun CM,
Italiano A and Sautes-Fridman C: B cells and tertiary lymphoid
structures as determinants of tumour immune contexture and clinical
outcome. Nat Rev Clin Oncol. 19:441–457. 2022.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Sato Y, Silina K, van den Broek M,
Hirahara K and Yanagita M: The roles of tertiary lymphoid
structures in chronic diseases. Nat Rev Nephrol. 19:525–537.
2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Teillaud JL, Houel A, Panouillot M,
Riffard C and Dieu-Nosjean MC: Tertiary lymphoid structures in
anticancer immunity. Nat Rev Cancer. 24:629–646. 2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhu Y, Zhou Z, Du X, Lin X, Liang ZM, Chen
S, Sun Y, Wang Y, Na Z, Wu Z, et al: Cancer cell-derived arginine
fuels polyamine biosynthesis in tumor-associated macrophages to
promote immune evasion. Cancer Cell. 43:1045–1060.e7.
2025.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tang Z, Bai Y, Fang Q, Yuan Y, Zeng Q,
Chen S, Xu T, Chen J, Tan L, Wang C, et al: Spatial transcriptomics
reveals tryptophan metabolism restricting maturation of
intratumoral tertiary lymphoid structures. Cancer Cell.
43:1025–1044.e14. 2025.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Vanhersecke L, Brunet M, Guégan JP, Rey C,
Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M,
et al: Mature tertiary lymphoid structures predict immune
checkpoint inhibitor efficacy in solid tumors independently of
PD-L1 expression. Nat Cancer. 2:794–802. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liu W, You W, Lan Z, Ren Y, Gao S, Li S,
Chen WW, Huang C, Zeng Y, Xiao N, et al: An immune cell map of
human lung adenocarcinoma development reveals an anti-tumoral role
of the Tfh-dependent tertiary lymphoid structure. Cell Rep Med.
5(101448)2024.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sadeghirad H, Monkman J, Tan CW, Liu N,
Yunis J, Donovan ML, Moradi A, Jhaveri N, Perry C, Adams MN, et al:
Spatial dynamics of tertiary lymphoid aggregates in head and neck
cancer: Insights into immunotherapy response. J Transl Med.
22(677)2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li K, Guo Q, Zhang X, Dong X, Liu W, Zhang
A, Li Y, Yan J, Jia G, Zheng Z, et al: Oral cancer-associated
tertiary lymphoid structures: Gene expression profile and
prognostic value. Clin Exp Immunol. 199:172–181. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Xu S, Han C, Zhou J, Yang D, Dong H, Zhang
Y, Zhao T, Tian Y and Wu Y: Distinct maturity and spatial
distribution of tertiary lymphoid structures in head and neck
squamous cell carcinoma: Implications for tumor immunity and
clinical outcomes. Cancer Immunol Immunother.
74(107)2025.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xin S, Wen S, He P, Zhao Y and Zhao H:
Density of tertiary lymphoid structures and their correlation with
prognosis in non-small cell lung cancer. Front Immunol.
15(1423775)2024.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Berthe J, Poudel P, Segerer FJ, Jennings
EC, Ng F, Surace M, Andoni A, Testori M, Saraiya M, Vuko M, et al:
Exploring the impact of tertiary lymphoid structures maturity in
NSCLC: Insights from TLS scoring. Front Immunol.
15(1422206)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Takeshita T, Yamamoto Y, Yamamoto-Ibusuki
M, Tomiguchi M, Sueta A, Murakami K and Iwase H: Clinical
significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and
ESR1 gene according to treatment lines in ER-positive breast
cancer. Mol Cancer. 17(67)2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Helmink BA, Reddy SM, Gao J, Zhang S,
Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, et
al: B cells and tertiary lymphoid structures promote immunotherapy
response. Nature. 577:549–555. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Posch F, Silina K, Leibl S, Mundlein A,
Moch H, Siebenhüner A, Samaras P, Riedl J, Stotz M, Szkandera J, et
al: Maturation of tertiary lymphoid structures and recurrence of
stage II and III colorectal cancer. Oncoimmunology.
7(e1378844)2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Overacre-Delgoffe AE, Bumgarner HJ, Cillo
AR, Burr AHP, Tometich JT, Bhattacharjee A, Bruno TC, Vignali DAA
and Hand TW: Microbiota-specific T follicular helper cells drive
tertiary lymphoid structures and anti-tumor immunity against
colorectal cancer. Immunity. 54:2812–2824.e4. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Hayashi Y, Makino T, Sato E, Ohshima K,
Nogi Y, Kanemura T, Honma K, Yamashita K, Saito T, Tanaka K, et al:
Density and maturity of peritumoral tertiary lymphoid structures in
oesophageal squamous cell carcinoma predicts patient survival and
response to immune checkpoint inhibitors. Brit J Cancer.
128:2175–2185. 2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wang Q, Shen X, An R, Bai J, Dong J, Cai
H, Zhu H, Zhong W, Chen W, Liu A and Du J: Peritumoral tertiary
lymphoid structure and tumor stroma percentage predict the
prognosis of patients with non-metastatic colorectal cancer. Front
Immunol. 13(962056)2022.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Li H, Liu H, Fu H, Li J, Xu L, Wang G and
Wu H: Peritumoral tertiary lymphoid structures correlate with
protective immunity and improved prognosis in patients with
hepatocellular carcinoma. Front Immunol. 12(648812)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Finkin S, Yuan D, Stein I, Taniguchi K,
Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran
G, et al: Ectopic lymphoid structures function as microniches for
tumor progenitor cells in hepatocellular carcinoma. Nat Immunol.
16:1235–1244. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
28
|
Cascone T, Leung CH, Weissferdt A, Pataer
A, Carter BW, Godoy MCB, Feldman H, William WN Jr, Xi Y, Basu S, et
al: Neoadjuvant chemotherapy plus nivolumab with or without
ipilimumab in operable non-small cell lung cancer: The phase 2
platform NEOSTAR trial. Nat Med. 29:593–604. 2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Savas P, Salgado R, Denkert C, Sotiriou C,
Darcy PK, Smyth MJ and Loi S: Clinical relevance of host immunity
in breast cancer: From TILs to the clinic. Nat Rev Clin Oncol.
13:228–241. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kinker GS, Vitiello GAF, Diniz AB,
Cabral-Piccin MP, Pereira PHB, Carvalho MLR, Ferreira WAS, Chaves
AS, Rondinelli A, Gusmão AF, et al: Mature tertiary lymphoid
structures are key niches of tumour-specific immune responses in
pancreatic ductal adenocarcinomas. Gut. 72:1927–1941.
2023.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Horeweg N, Workel HH, Loiero D, Church DN,
Vermij L, Léon-Castillo A, Krog RT, de Boer SM, Nout RA, Powell ME,
et al: Tertiary lymphoid structures critical for prognosis in
endometrial cancer patients. Nat Commun. 13(1373)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ahuja S, Khan AA, Zaheer S and Ranga S:
Tumor-infiltrating lymphocytes in oral cavity squamous cell
carcinoma and its association with clinicopathological parameters.
Pathol Res Pract. 251(154882)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Li S, Zhang N, Zhang H, Yang Z, Cheng Q,
Wei K, Zhou M and Huang C: Deciphering the role of LGALS2: insights
into tertiary lymphoid structure-associated dendritic cell
activation and immunotherapeutic potential in breast cancer
patients. Mol Cancer. 23(216)2024.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Cabrita R, Lauss M, Sanna A, Donia M,
Skaarup LM, Mitra S, Johansson I, Phung B, Harbst K,
Vallon-Christersson J, et al: Tertiary lymphoid structures improve
immunotherapy and survival in melanoma. Nature. 577:561–565.
2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ding GY, Ma JQ, Yun JP, Chen X, Ling Y,
Zhang S, Shi JY, Chang YQ, Ji Y, Wang XY, et al: Distribution and
density of tertiary lymphoid structures predict clinical outcome in
intrahepatic cholangiocarcinoma. J Hepatol. 76:608–618.
2022.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Xiang Z, Wei X, Zhang Z, Tang Y, Chen L,
Tan C, Zeng Y, Wang J, Zhao G, Dai Z, et al: Efficacy, safety and
single-cell analysis of neoadjuvant immunochemotherapy in locally
advanced oral squamous cell carcinoma: A phase II trial. Nat
Commun. 16(3968)2025.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ruiz-Torres DA, Bryan ME, Hirayama S,
Merkin RD, Luciani E, Roberts TJ, Patel M, Park JC, Wirth LJ, Sadow
PM, et al: Spatial characterization of tertiary lymphoid structures
as predictive biomarkers for immune checkpoint blockade in head and
neck squamous cell carcinoma. Oncoimmunology.
14(2466308)2025.PubMed/NCBI View Article : Google Scholar
|
|
38
|
He M, He Q, Cai X, Liu J, Deng H, Li F,
Zhong R, Lu Y, Peng H, Wu X, et al: Intratumoral tertiary lymphoid
structure (TLS) maturation is influenced by draining lymph nodes of
lung cancer. J Immunother Cancer 11: J Immunother Cancer.
11(e005539)2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Guo X, Xu L, Nie L, Zhang C, Liu Y, Zhao
R, Cao J, Tian L and Liu M: B cells in head and neck squamous cell
carcinoma: Current opinion and novel therapy. Cancer Cell Int.
24(41)2024.PubMed/NCBI View Article : Google Scholar
|
|
40
|
An Y, Sun JX, Xu MY, Xu JZ, Ma SY, Liu CQ,
Liu Z, Wang SG and Xia QD: Tertiary lymphoid structure patterns aid
in identification of tumor microenvironment infiltration and
selection of therapeutic agents in bladder cancer. Front Immunol.
13(1049884)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Liang H, Zhang Z, Guan Z, Zheng S, Lou J,
Liu W, Cai Q and Si Y: Follicle-like tertiary lymphoid structures:
A potential biomarker for prognosis and immunotherapy response in
patients with laryngeal squamous cell carcinoma. Front Immunol.
14(1096220)2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Patil NS, Nabet BY, Müller S, Koeppen H,
Zou W, Giltnane J, Au-Yeung A, Srivats S, Cheng JH, Takahashi C, et
al: Intratumoral plasma cells predict outcomes to PD-L1 blockade in
non-small cell lung cancer. Cancer Cell. 40:289–300.e4.
2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tanaka T, Masuda A, Inoue J, Hamada T,
Ikegawa T, Toyama H, Sofue K, Shiomi H, Sakai A, Kobayashi T, et
al: Integrated analysis of tertiary lymphoid structures in relation
to tumor-infiltrating lymphocytes and patient survival in
pancreatic ductal adenocarcinoma. J Gastroenterol. 58:277–291.
2023.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Delvecchio FR, Fincham REA, Spear S, Clear
A, Roy-Luzarraga M, Balkwill FR, Gribben JG, Bombardieri M,
Hodivala-Dilke K, Capasso M and Kocher HM: Pancreatic cancer
chemotherapy is potentiated by induction of tertiary lymphoid
structures in mice. Cell Mol Gastroenter. 12:1543–1565.
2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhang Y, Xu M, Ren Y, Ba Y, Liu S, Zuo A,
Xu H, Weng S, Han X and Liu Z: Tertiary lymphoid structural
heterogeneity determines tumour immunity and prospects for clinical
application. Mol Cancer. 23(75)2024.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Lin Z, Huang L, Li S, Gu J, Cui X and Zhou
Y: Pan-cancer analysis of genomic properties and clinical outcome
associated with tumor tertiary lymphoid structure. Sci Rep.
10(21530)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Cillo AR, Kurten CHL, Tabib T, Qi Z, Onkar
S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, et al: Immune
landscape of viral- and carcinogen-driven head and neck cancer.
Immunity. 52:183–199.e9. 2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Ruffin AT, Cillo AR, Tabib T, Liu A, Onkar
S, Kunning SR, Lampenfeld C, Atiya HI, Abecassis I, Kürten CHL, et
al: B cell signatures and tertiary lymphoid structures contribute
to outcome in head and neck squamous cell carcinoma. Nat Commun.
12(3349)2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hu C, You W, Kong D, Huang Y, Lu J, Zhao
M, Jin Y, Peng R, Hua D, Kuang DM and Chen Y: Tertiary lymphoid
structure-associated B cells enhance
CXCL13+CD103+CD8+Trm cell response to PD-1
blockade in gastric cancer. Gastroenterology: Oct 27:
S0016-5085(23)05198-3, 2023 (Epub ahead of print).
|
|
50
|
Liu Z, Meng X, Tang X, Zou W and He Y:
Intratumoral tertiary lymphoid structures promote patient survival
and immunotherapy response in head neck squamous cell carcinoma.
Cancer Immunol Immun. 72:1505–1521. 2023.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Muralidharan S, Nikalje M, Subramaniam T,
Koshy JA, Koshy AV and Bangera D: A narrative review on oral
squamous cell carcinoma. J Pharm Bioallied Sci. 17 (Suppl
1):S204–S206. 2025.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Hosseini TM, Park SJ and Guo T: The
mutational and microenvironmental landscape of cutaneous squamous
cell carcinoma: A review. Cancers (Basel). 16(2904)2024.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Bossi P, Resteghini C, Paielli N, Licitra
L, Pilotti S and Perrone F: Prognostic and predictive value of EGFR
in head and neck squamous cell carcinoma. Oncotarget.
7:74362–74379. 2016.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Karabajakian A, Bouaoud J, Michon L, Kamal
M, Crozes C, Zrounba P, Auclair-Perossier J, Gadot N, Attignon V,
Le Tourneau C, et al: Longitudinal assessment of PD-L1 expression
and gene expression profiles in patients with head and neck cancer
reveals temporal heterogeneity. Oral Oncol.
119(105368)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Alessandrini L, Franz L, Ottaviano G, Ghi
MG, Lanza C, Blandamura S and Marioni G: Prognostic role of
programmed death ligand 1 (PD-L1) and the immune microenvironment
in laryngeal carcinoma. Oral Oncol. 108(104836)2020.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Li H, Zhang MJ, Zhang B, Lin WP, Li SJ,
Xiong D, Wang Q, Wang WD, Yang QC, Huang CF, et al: Mature tertiary
lymphoid structures evoke intra-tumoral T and B cell responses via
progenitor exhausted CD4+ T cells in head and neck
cancer. Nat Commun. 16(4228)2025.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Zhang J, Zeng L, Song G, Peng G, Chen Z,
Yuan Y, Chen T, Zhong T, Chen S, Luo Z, et al: A novel tertiary
lymphoid structure-associated signature accurately predicts patient
prognosis and facilitates the selection of personalized treatment
strategies for HNSCC. Front Immunol. 16(1551844)2025.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Lin X, Zhao X, Chen Y, Yang R, Dai Z, Li
W, Lin C and Cao W: CXC ligand 13 orchestrates an immunoactive
microenvironment and enhances immunotherapy response in head and
neck squamous cell carcinoma. Int J Immunopathol Pharmacol.
38(3946320241227312)2024.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Bao J, Betzler AC, Hess J and Brunner C:
Exploring the dual role of B cells in solid tumors: Implications
for head and neck squamous cell carcinoma. Front Immunol.
14(1233085)2023.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Xing A, Lv D, Wu C, Zhou K, Zhao T, Zhao
L, Wang H and Feng H: Tertiary lymphoid structures gene signature
predicts prognosis and immune infiltration analysis in head and
neck squamous cell carcinoma. Curr Genomics. 25:88–104.
2024.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Hong S, Wang Q, Yu D, Zheng J, Huang P, Gu
J and Zhang Y: Tertiary lymphoid structures in head and neck
squamous cell carcinoma (Review). Oncol Rep. 54(76)2025.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Gavrielatou N, Fortis E, Spathis A,
Anastasiou M, Economopoulou P, Foukas GRP, Lelegiannis IM,
Rusakiewicz S, Vathiotis I, Aung TN, et al: B-cell infiltration is
associated with survival outcomes following programmed cell death
protein 1 inhibition in head and neck squamous cell carcinoma. Ann
Oncol. 35:340–350. 2024.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Wu F, Cao H, Ren S, Wu J, Liu X, Li Q, Xu
Q, Chen J, Wang R, Chen S, et al: Tertiary lymphoid
structure-related score as a predictor for survival prognosis and
immunotherapy response in head and neck squamous cell carcinoma.
Front Immunol. 15(1483497)2024.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Peng Y, Xiao L, Rong H, Ou Z, Cai T, Liu
N, Li B, Zhang L, Wu F, Lan T, et al: Single-cell profiling of
tumor-infiltrating TCF1/TCF7+ T cells reveals a T
lymphocyte subset associated with tertiary lymphoid
structures/organs and a superior prognosis in oral cancer. Oral
Oncol. 119(105348)2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Lechner A, Schlößer HA, Thelen M, Wennhold
K, Rothschild SI, Gilles R, Quaas A, Siefer OG, Huebbers CU,
Cukuroglu E, et al: Tumor-associated B cells and humoral immune
response in head and neck squamous cell carcinoma. Oncoimmunology.
8(1535293)2019.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Secrier M, McGrath L, Ng F, Gulati S,
Raymond A, Nuttall BRB, Berthe J, Jones EV, Sidders BS, Galon J, et
al: Immune cell abundance and T-cell receptor landscapes suggest
new patient stratification strategies in head and neck squamous
cell carcinoma. Cancer Res Commun. 3:2133–2145. 2023.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Almangush A, Bello IO, Elseragy A,
Hagström J, Haglund C, Kowalski LP, Nieminen P, Coletta RD, Mäkitie
AA, Salo T and Leivo I: Tertiary lymphoid structures associate with
improved survival in early oral tongue cancer. BMC Cancer.
22(1108)2022.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Wang C, Huang Z, Zhang M, Xiong G, Chen X
and Xie N: Prognostic value of tertiary lymphoid structures in
early clinical stage oral tongue squamous cell carcinoma. J Oral
Pathol Med. 50:776–784. 2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Zhang L, Ren S, Lan T, Marco V, Liu N, Wei
B, Chen Y, Wu J, Li Q, Wu F, et al: Mature tertiary lymphoid
structures linked to HPV status and anti-PD-1 based
chemoimmunotherapy response in head and neck squamous cell
carcinoma. Oncoimmunology. 14(2528109)2025.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Li H, Zhu SW, Zhou JJ, Chen DR, Liu J, Wu
ZZ, Wang WY, Zhang MJ and Sun ZJ: Tertiary lymphoid structure
raises survival and immunotherapy in HPV-HNSCC. J Dent Res.
102:678–688. 2023.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Li Q, Liu X, Wang D, Wang Y, Lu H, Wen S,
Fang J, Cheng B and Wang Z: Prognostic value of tertiary lymphoid
structure and tumour infiltrating lymphocytes in oral squamous cell
carcinoma. Int J Oral Sci. 12(24)2020.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Chang TG, Spathis A, Schäffer AA,
Gavrielatou N, Kuo F, Jia D, Mukherjee S, Sievers C, Economopoulou
P, Anastasiou M, et al: Tumor and blood B-cell abundance
outperforms established immune checkpoint blockade response
prediction signatures in head and neck cancer. Ann Oncol.
36:309–320. 2025.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Ning J, Hao J, Guo F, Hou X, Li L, Wang J,
Wang S, Gao Y, Zheng X and Gao M: ABCB11 accumulated in immature
tertiary lymphoid structures participates in xenobiotic metabolic
process and predicts resistance to PD-1/PD-L1 inhibitors in head
and neck squamous cell carcinoma. Transl Oncol.
36(101747)2023.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Zhu J, Lu H, Wang K, Liu B and Yan J:
Tertiary lymphoid structures in head and neck squamous cell
carcinoma. Transl Oncol. 44(101949)2024.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Weed DT, Zilio S, McGee C, Marnissi B,
Sargi Z, Franzmann E, Thomas G, Leibowitz J, Nicolli E, Arnold D,
et al: The tumor immune microenvironment architecture correlates
with risk of recurrence in head and neck squamous cell carcinoma.
Cancer Res. 83:3886–3900. 2023.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Shu DH, Ho WJ, Kagohara LT, Girgis A, Shin
SM, Danilova L, Lee JW, Sidiropoulos DN, Mitchell S, Munjal K, et
al: Immunotherapy response induces divergent tertiary lymphoid
structure morphologies in hepatocellular carcinoma. Nat Immunol.
25:2110–2123. 2024.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Kroeger DR, Milne K and Nelson BH:
Tumor-infiltrating plasma cells are associated with tertiary
lymphoid structures, cytolytic T-cell responses, and superior
prognosis in ovarian cancer. Clin Cancer Res. 22:3005–3015.
2016.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Wang M, Zhai R, Wang M, Zhu W, Zhang J, Yu
M, Zhang W, Ye J and Liu L: Tertiary lymphoid structures in head
and neck squamous cell carcinoma improve prognosis by recruiting
CD8+ T cells. Mol Oncol. 17:1514–1530. 2023.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Xian S, Dosset M, Castro A, Carter H and
Zanetti M: Transcriptional analysis links B cells and TERT
expression to favorable prognosis in head and neck cancer. PNAS
Nexus. 2(pgad046)2023.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Shen S, Cui Y, Li M, Yu K, Zhu Q, Zhang X,
Shen W, Li H, Jiang H, Li M, et al: Toll-like receptor agonists
promote the formation of tertiary lymphoid structure and improve
anti-glioma immunity. Neuro Oncol. 27:140–154. 2025.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Chelvanambi M, Fecek RJ, Taylor JL and
Storkus WJ: STING agonist-based treatment promotes vascular
normalization and tertiary lymphoid structure formation in the
therapeutic melanoma microenvironment. J Immunother Cancer.
9(e001906)2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Sweeney KJ, Tetzlaff MT, Vega F,
Gillenwater A, Zuo Z, Gross N, Nagarajan P, Wargo J, Nelson K,
Prieto VG, et al: Tertiary lymphoid structures with overlapping
histopathologic features of cutaneous marginal zone lymphoma during
neoadjuvant cemiplimab therapy are associated with antitumor
response. J Cutan Pathol. 48:674–679. 2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Wang Q, Sun K, Liu R, Song Y, Lv Y, Bi P,
Yang F, Li S, Zhao J, Li X, et al: Single-cell transcriptome
sequencing of B-cell heterogeneity and tertiary lymphoid structure
predicts breast cancer prognosis and neoadjuvant therapy efficacy.
Clin Transl Med. 13(e1346)2023.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Fabian KP, Santiago-Sanchez G, Padget MR,
Lassoued W, Allen CT, Battula S, Kaufman H and Hodge JW:
Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune
checkpoint blockade enhanced antitumor immune responses in head and
neck cancer models. J Immunother Cancer. 12(e009712)2024.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Clubb JHA, Kudling TV, Heiniö C, Basnet S,
Pakola S, Cervera Carrascón V, Santos JM, Quixabeira DCA, Havunen
R, Sorsa S, et al: Adenovirus Encoding tumor necrosis factor alpha
and interleukin 2 induces a tertiary lymphoid structure signature
in immune checkpoint inhibitor refractory head and neck cancer.
Front Immunol. 13(794251)2022.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Ruiz-Torres DA, Wise JF, Zhao BY,
Oliveira-Costa JP, Cavallaro S, Sadow PM, Fang J, Yilmaz O, Patel
A, Loosbroock C, et al: Dendritic cell effector mechanisms and
tumor immune microenvironment infiltration define TLR8 modulation
and PD-1 blockade. Front Immunol. 15(1440530)2024.PubMed/NCBI View Article : Google Scholar
|
